Linsitinib (OSI-906)

目录号:S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活,IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体,具有良好的代谢稳定性。OSI-906浓度为1μM时,完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖,包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系,EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M{TiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXMcFVnUUN3ME2wMlAzQDB4IN88US=> NYXYb3NYW0GQR1XS
KS-1 NGnOXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTlfWVGUUN3ME2wMlA{QDN3IN88US=> NIf1[|RUSU6JRWK=
TE-11 NXvFWXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLpfIhKSzVyPUCuNFc5OjJizszN NHrnUppUSU6JRWK=
EW-1 M{flTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[5PGlEPTB;MD6wPFU5PSEQvF2= M3zJb3NCVkeHUh?=
HMV-II MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEi4OFYh|ryP MljHV2FPT0WU
COLO-205 M4jxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMUC0OVQh|ryP NV7OVVJRW0GQR1XS
ES1 NGPLfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLtTWM2OD1yLkGwOlk3KM7:TR?= M1nSNnNCVkeHUh?=
GDM-1 NETYdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HLbGlEPTB;MD6xN|Y4OiEQvF2= NFjaTYFUSU6JRWK=
ML-2 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnHNo5SUUN3ME2wMlE2QDl4IN88US=> MojNV2FPT0WU
Saos-2 NWnlWXZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Dlb2lEPTB;MD6xOlUzPiEQvF2= NY[1ZVFnW0GQR1XS
NCI-H1355 NVfHO2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTiTWM2OD1yLkG4NVM2KM7:TR?= NFjYZnhUSU6JRWK=
G-401 M{PqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrVbJlKSzVyPUCuNVgzOyEQvF2= NEDHSohUSU6JRWK=
EW-16 NVuwcIM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTYUnZNUUN3ME2wMlE5Pzd5IN88US=> NFHEOGVUSU6JRWK=
EW-7 NGD2bmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMUi4PFEh|ryP NGTl[ldUSU6JRWK=
NCI-H727 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUm3PVQh|ryP NHPxNXlUSU6JRWK=
LCLC-97TM1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rJbWlEPTB;MD6yNFk2PSEQvF2= MVjTRW5ITVJ?
NCI-H650 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTNTWM2OD1yLkKxN|g1KM7:TR?= MULTRW5ITVJ?
NCI-H2122 NU\4PHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrqSI9KSzVyPUCuNlMzQTlizszN MVnTRW5ITVJ?
SK-N-DZ NVfNOItvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMkO2PVgh|ryP MV\TRW5ITVJ?
HT-29 M2LZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVflSHhDUUN3ME2wMlI1OjR6IN88US=> MojSV2FPT0WU
LB771-HNC MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LZfGlEPTB;MD6yOVkyPSEQvF2= M2SydHNCVkeHUh?=
HT-144 NIf4PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrwZWRqUUN3ME2wMlI3OTlzIN88US=> MYjTRW5ITVJ?
LAN-6 M2rZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMk[zOFgh|ryP M3zEXnNCVkeHUh?=
EW-18 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PmWmlEPTB;MD6yO|AxOSEQvF2= M{\TfnNCVkeHUh?=
LS-1034 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjDSIQ2UUN3ME2wMlI4OTN{IN88US=> MkLOV2FPT0WU
EW-11 M{Xhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vnd2lEPTB;MD6yPFQ{OiEQvF2= NU\BN|V7W0GQR1XS
SNU-C1 NWXVXlRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMkmzNVMh|ryP M4\xeHNCVkeHUh?=
RS4-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwM{O3OVgh|ryP MkDFV2FPT0WU
ES4 M3W5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ntT2lEPTB;MD60NVA{QCEQvF2= MW\TRW5ITVJ?
COLO-320-HSR MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e4ZWlEPTB;MD60NVM3QCEQvF2= NGWzUmFUSU6JRWK=
NB10 NX70fGdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G0NWlEPTB;MD60OVQ{PyEQvF2= MkC3V2FPT0WU
BFTC-905 M3fJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnwTIZXUUN3ME2wMlQ3PzV6IN88US=> MljEV2FPT0WU
A375 M3;oRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;mWohKSzVyPUCuOFc3OTdizszN Ml\mV2FPT0WU
SJRH30 NWPWTI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHwTWM2OD1yLkWwPFIzKM7:TR?= NUDUfXZwW0GQR1XS
NOS-1 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\JUXZKSzVyPUCuOVIzPjdizszN M12xOXNCVkeHUh?=
SIG-M5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL4TWM2OD1yLkWzOVU4KM7:TR?= M1O0fHNCVkeHUh?=
DOK M{jzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L3cmlEPTB;MD61OVYh|ryP NFz3To5USU6JRWK=
NB69 NV;sR4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNUiyOVch|ryP M37Dd3NCVkeHUh?=
SK-NEP-1 NUL1fZpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXX[oFKSzVyPUCuOlAzOzZizszN MmPCV2FPT0WU
SK-MM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPEe4hKSzVyPUCuOlU1QTFizszN MUDTRW5ITVJ?
NCI-H358 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNkewPFIh|ryP NVvGdYJIW0GQR1XS
RH-1 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fleWlEPTB;MD63OFg2QSEQvF2= NF7yZ3dUSU6JRWK=
NH-12 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwN{[wOFYh|ryP MV3TRW5ITVJ?
TE-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwN{[0PFYh|ryP MWLTRW5ITVJ?
COLO-668 NFLjUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDtZVk4UUN3ME2wMlg1PjZ4IN88US=> NIXW[3hUSU6JRWK=
PANC-08-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\zTWM2OD1yLki2N|c4KM7:TR?= M3TZXnNCVkeHUh?=
HCC2998 M33kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L6dGlEPTB;MD64PFI3OyEQvF2= M3;iV3NCVkeHUh?=
ABC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v1VWlEPTB;MD65NFM2OiEQvF2= MWfTRW5ITVJ?
ES6 M1zuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vpfmlEPTB;MD65NVA3PiEQvF2= MUnTRW5ITVJ?
SNU-387 M1fmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrLTWM2OD1yLkm5N|k{KM7:TR?= MnHVV2FPT0WU
CMK NFz0S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X1NWlEPTB;MD65PVkzQSEQvF2= MlzzV2FPT0WU
SJSA-1 NVTaRWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnewTWM2OD1zLkCzOlU{KM7:TR?= NIHZNphUSU6JRWK=
SIMA NYnpPGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPPdJRpUUN3ME2xMlA3QDJ3IN88US=> MY\TRW5ITVJ?
ES3 NWrrU5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;3UodHUUN3ME2xMlEzOjl5IN88US=> Mn31V2FPT0WU
IGROV-1 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoriTWM2OD1zLkG1OFQ1KM7:TR?= NIDZWXlUSU6JRWK=
MEL-JUSO M2nmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr2[4tSUUN3ME2xMlE2PzV7IN88US=> NHe3cZlUSU6JRWK=
T84 NGLrd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwMkC5NVQh|ryP M{LCOHNCVkeHUh?=
CAL-85-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwMkOxN|gh|ryP M3vRNXNCVkeHUh?=
RD MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWzVY45UUN3ME2xMlI3PDV3IN88US=> M3jwO3NCVkeHUh?=
TE-8 M3HIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\lNGlEPTB;MT6zNVQ3OiEQvF2= NIi2fXNUSU6JRWK=
L-363 NYnORVluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLZTWM2OD1zLkO0NlA5KM7:TR?= NYjEVpZRW0GQR1XS
EKVX MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kTWM2OD1zLkO0OVY5KM7:TR?= MYnTRW5ITVJ?
SK-MEL-3 M{HkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWThPYRxUUN3ME2xMlQ5PTV4IN88US=> MX;TRW5ITVJ?
TGBC24TKB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX4S5dKSzVyPUGuOVAyQTNizszN M3n5T3NCVkeHUh?=
NCI-H1770 NWnhN|ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwNUGxNVMh|ryP NWXHS4V3W0GQR1XS
HuH-7 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLKTWM2OD1zLk[wNFk5KM7:TR?= NWjrcXpIW0GQR1XS
HL-60 M4\SUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwNk[5Nlgh|ryP MU\TRW5ITVJ?
TE-1 NXjhZ4diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLKTWM2OD1zLkewPVQ2KM7:TR?= NYfxUGV5W0GQR1XS
LC-2-ad NVnN[|V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyzOpJ3UUN3ME2xMlc{QDh5IN88US=> NInXc|BUSU6JRWK=
LB647-SCLC M{fufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ZTWM2OD1zLke2OVg{KM7:TR?= M365TnNCVkeHUh?=
NCI-H2171 NHfjdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuzWXVsUUN3ME2xMlc4PzF4IN88US=> MlzEV2FPT0WU
SK-PN-DW NYXq[4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jSR2lEPTB;MT65NVI6QCEQvF2= NEHwUGRUSU6JRWK=
MC-IXC MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwOUi5PEDPxE1? M{[5enNCVkeHUh?=
LS-513 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXWUG5KSzVyPUKuNFU{ODVizszN NYnzSHVbW0GQR1XS
EW-3 M3XuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnIbpBKSzVyPUKuNFk5PDRizszN M1LRTXNCVkeHUh?=
OPM-2 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPNXVhKSzVyPUKuNVAzKM7:TR?= NXnoWYQ6W0GQR1XS
LP-1 NIq5TopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr6TmV4UUN3ME2yMlI2QDB5IN88US=> MoS4V2FPT0WU
LU-134-A NHLrPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfndpF{UUN3ME2yMlI4PyEQvF2= M1:3WXNCVkeHUh?=
CP66-MEL MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHmV|V6UUN3ME2yMlI6ODF2IN88US=> NHvzXI5USU6JRWK=
HCC1143 M4\RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwNEWzOlgh|ryP M4W2dHNCVkeHUh?=
LOXIMVI M3vMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXlTWM2OD1{Lk[wNlEh|ryP MlHVV2FPT0WU
TE-10 NETNZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvPd25KSzVyPUKuO|A5OzhizszN NUm0UlFSW0GQR1XS
NCI-H1882 M33RSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[5dnd{UUN3ME2yMlc2OjJ5IN88US=> NULD[ldEW0GQR1XS
CHP-126 NUHoSGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrKNWJPUUN3ME2yMlc3OzF5IN88US=> MYDTRW5ITVJ?
NCI-H1623 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjqTWM2OD1{LkmyNFI1KM7:TR?= NWKwNnhNW0GQR1XS
GB-1 M{DMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrJVWxXUUN3ME2yMlk{PDB2IN88US=> NEHjSVZUSU6JRWK=
RCC10RGB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TjeWlEPTB;Mj65OVI5OSEQvF2= NXzOSllSW0GQR1XS
NCI-H2141 NVSxNVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjOUZFKSzVyPUKuPVY5QTZizszN MV\TRW5ITVJ?
GI-ME-N M3XPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNwMEC1OlUh|ryP MXrTRW5ITVJ?
NCI-H526 NXGwXpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T4dmlEPTB;Mz6wOFA5PSEQvF2= M3HxenNCVkeHUh?=
NCI-H747 M3rERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3vflFKSzVyPUOuNFQ6QTJizszN MVPTRW5ITVJ?
SNU-423 M1y5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXLdFhDUUN3ME2zMlIxOzF|IN88US=> MoTrV2FPT0WU
A427 NHGzOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;4TWM2OD1|LkK1Olk6KM7:TR?= M{PVNXNCVkeHUh?=
CAL-12T NYfRWI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC4TWM2OD1|LkSwO|E{KM7:TR?= M4G0OnNCVkeHUh?=
LU-99A NFHTUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\mVlJKSzVyPUOuOFcyODVizszN NXzpV2tEW0GQR1XS
MS-1 NIn4XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXBVXFNUUN3ME2zMlU{PDJ7IN88US=> NHWyV|RUSU6JRWK=
SK-LU-1 NYC4SGx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfzWWdKSzVyPUOuO|YzQTVizszN NH7P[WtUSU6JRWK=
SW837 NX7zfIE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLRWYVVUUN3ME2zMlc3OzN|IN88US=> M17VeXNCVkeHUh?=
ES8 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfwZ25KSzVyPUOuPFM5PzdizszN MmmyV2FPT0WU
MZ2-MEL NET4NpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTNwOUKwPFYh|ryP NFrqT4FUSU6JRWK=
TGW NYm0blFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTRwMEGzNVEh|ryP MV\TRW5ITVJ?
GP5d M3XP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vFcmlEPTB;ND6wOVM3OiEQvF2= MmD1V2FPT0WU
BB49-HNC NEfmRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7wRZAzUUN3ME20MlE2OjF|IN88US=> M1S1cXNCVkeHUh?=
NB13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTJTWM2OD12LkK2PFg4KM7:TR?= M13Vd3NCVkeHUh?=
NTERA-S-cl-D1 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRwMki2NVUh|ryP NFGzb5dUSU6JRWK=
NCI-H1648 MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRwMkm4NVkh|ryP M1rsTXNCVkeHUh?=
LCLC-103H NWjFRYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTRwM{KxPVUh|ryP MknZV2FPT0WU
LS-411N NXe2V5NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LBemlEPTB;ND60OFg5PSEQvF2= M3vPVHNCVkeHUh?=
NCI-H1092 NILEXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjUfWJwUUN3ME20MlQ2Pjh5IN88US=> MUTTRW5ITVJ?
PANC-10-05 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTMTWM2OD12Lk[5PFQh|ryP NXLFNnJFW0GQR1XS
DK-MG NGDJVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TkdGlEPTB;ND64NFk{OyEQvF2= NHXzfVFUSU6JRWK=
OVCAR-5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX3TZZ7UUN3ME20MlgyOjJ4IN88US=> NGjPbIhUSU6JRWK=
CAL-39 NV7FZ4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRwOEe2O{DPxE1? M2HpTHNCVkeHUh?=
TE-441-T NF24bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS1TYRKSzVyPUSuPVA2OzdizszN MU\TRW5ITVJ?
MOLT-16 NF;QN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTRwOUWyOVMh|ryP MUXTRW5ITVJ?
MCF7 NF63[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS3OWxRUUN3ME21MlE1PTF5IN88US=> Mk\hV2FPT0WU
CAPAN-1 M3H3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnjVFVJUUN3ME21MlI2PzB5IN88US=> MlzIV2FPT0WU
PSN1 M2\D[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTVwMkeyN|Uh|ryP NUiyNYl4W0GQR1XS
NCI-H292 M3zSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Kz[2lEPTB;NT6zNFA1PCEQvF2= NYf4ToxlW0GQR1XS
CPC-N M1nndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuxTWM2OD13LkO5OFE6KM7:TR?= NWfLTpV1W0GQR1XS
DoTc2-4510 NYLKUHFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW3Smc4UUN3ME21MlQ2OzdzIN88US=> MVjTRW5ITVJ?
LB1047-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHOUWlKSzVyPUWuOVU6OzNizszN MWrTRW5ITVJ?
MHH-ES-1 M2XvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULMcpZlUUN3ME21MlU6QTB5IN88US=> NHLRfHNUSU6JRWK=
NMC-G1 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF23dFJKSzVyPUWuO|AzOjdizszN MU\TRW5ITVJ?
SW1710 NGPnZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrLTY5KUUN3ME21Mlc1PzVzIN88US=> M1jsWHNCVkeHUh?=
YAPC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXacIRyUUN3ME21Mlc3OjBzIN88US=> NVjSXYs{W0GQR1XS
22RV1 NF32dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWxTWM2OD13LkiwNFE6KM7:TR?= NEXRd2ZUSU6JRWK=
COLO-679 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nmPGlEPTB;NT64PFk1QCEQvF2= M3\6VHNCVkeHUh?=
TCCSUP MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnJTWM2OD13LkmzNlU6KM7:TR?= MXPTRW5ITVJ?
C2BBe1 MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTiWHJZUUN3ME21Mlk{QTdizszN MlzuV2FPT0WU
TE-15 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLNTWM2OD14LkC2OlA2KM7:TR?= NYnVVYZlW0GQR1XS
SCLC-21H NEjHRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfjTmQ1UUN3ME22MlExQDR|IN88US=> NXL0O5lnW0GQR1XS
EoL-1-cell MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIThclBKSzVyPU[uNVY2PjNizszN MY\TRW5ITVJ?
NKM-1 NXfCO5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInxXFFKSzVyPU[uNVY4OSEQvF2= NULyRXlXW0GQR1XS
NCI-H1304 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HyWWlEPTB;Nj6yO|QzQCEQvF2= MnnGV2FPT0WU
NB6 NFnYe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\hTWM2OD14LkK5OlIzKM7:TR?= M33LOnNCVkeHUh?=
NALM-6 M1vnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnaR2prUUN3ME22MlM{OjNizszN NFnKbXNUSU6JRWK=
NCI-H522 M{XyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvuTWM2OD14LkOzN|A3KM7:TR?= NIS0cWJUSU6JRWK=
MV-4-11 NWHXVHd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz4TWM2OD14LkO3NFc6KM7:TR?= MU\TRW5ITVJ?
LB2241-RCC NEXpd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnYWYlKSzVyPU[uN|g3PjdizszN NGTKXmVUSU6JRWK=
NCI-H1417 NGnTR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfveYJ6UUN3ME22MlQxQDR5IN88US=> NVr0VnIxW0GQR1XS
HT-1197 NEDJTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm1WmtiUUN3ME22MlU4OTJ{IN88US=> NVnEWINPW0GQR1XS
P30-OHK NXv4RpBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37lSmlEPTB;Nj62Nlc4KM7:TR?= M1P4dXNCVkeHUh?=
ALL-PO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXQNVhKSzVyPU[uO|E6OTZizszN MVLTRW5ITVJ?
OVCAR-4 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G1dmlEPTB;Nj63OVQxPSEQvF2= NVX6XXhpW0GQR1XS
HCC2157 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWiyd5dQUUN3ME22Mlc4PDd3IN88US=> NFO0NlZUSU6JRWK=
NCI-H838 M2HnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZwOU[0PUDPxE1? NFfwcoNUSU6JRWK=
NCI-H1299 MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLZOnBHUUN3ME22Mlk4ODlizszN M1HqXHNCVkeHUh?=
SW954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTdwMkCwOlgh|ryP MlH2V2FPT0WU
NCI-H441 M1q2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HyR2lEPTB;Nz6zOFA3PSEQvF2= MYTTRW5ITVJ?
SK-MEL-2 M1rMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfCOZdKSzVyPUeuOFg{PzNizszN MX7TRW5ITVJ?
KARPAS-45 NWjPNJBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7QTWM2OD15Lk[1PVI6KM7:TR?= MULTRW5ITVJ?
CAL-54 M3PsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzWOpVKSzVyPUeuPFI6PzdizszN NHPBRXpUSU6JRWK=
KYSE-180 NIfmSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfHeW9uUUN3ME23Mlg5QTRzIN88US=> M3ruenNCVkeHUh?=
NCI-H187 NVzX[49yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPyTZhEUUN3ME23Mlk2QTR5IN88US=> NHm3WXZUSU6JRWK=
RT-112 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HoTmlEPTB;OD6wPVY4PyEQvF2= M4TJSHNCVkeHUh?=
NCI-H1437 NHv6WFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fLS2lEPTB;OD6wPVc6PSEQvF2= NWjKflJVW0GQR1XS
SNU-449 NXn3Xo14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrkSmlOUUN3ME24MlI5Ojd{IN88US=> MlH2V2FPT0WU
HCC1187 NHzvOINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HTeWlEPTB;OD6yPVM6OSEQvF2= NIf1PGZUSU6JRWK=
NCI-H2030 M1uxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRThwM{e3NVQh|ryP NFS5[llUSU6JRWK=
HuO-3N1 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLvUHNGUUN3ME24MlM4QDR2IN88US=> MYTTRW5ITVJ?
COLO-792 M2KxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3WfmNKSzVyPUiuOFE2OjdizszN MlrNV2FPT0WU
MIA-PaCa-2 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO4WIZmUUN3ME24Mlg2PTB6IN88US=> Mlm3V2FPT0WU
SK-N-FI NYfjXmpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXfmlEPTB;OT6wOFI2KM7:TR?= NEXET3lUSU6JRWK=
MMAC-SF M17lVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fOUGlEPTB;OT6wPVc2OSEQvF2= MoLaV2FPT0WU
NCI-H28 NVi4Xpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LoXGlEPTB;OT6xNFQ3QSEQvF2= NGnrenJUSU6JRWK=
ETK-1 NFTpW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDcmVKSzVyPUmuNlk6PzRizszN MYLTRW5ITVJ?
NCI-H1993 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i2SmlEPTB;OT60OFI3OSEQvF2= M3vs[HNCVkeHUh?=
no-11 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlwNEexNkDPxE1? NGjaS2dUSU6JRWK=
ChaGo-K-1 MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT4THNKUUN3ME25MlUyPTh|IN88US=> MYfTRW5ITVJ?
NCCIT NUXse5htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC1[ZFKSzVyPUmuOVMyPjlizszN MlHEV2FPT0WU
SAS NXXKW49VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrleGNIUUN3ME2xNE4zPDhizszN NWHsZ|ZXW0GQR1XS
A673 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fGZmlEPTB;MUCuN|cxPCEQvF2= NEjiTVhUSU6JRWK=
NCI-H1522 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nLSGlEPTB;MUCuN|cxPyEQvF2= M1P2eXNCVkeHUh?=
NCI-H810 M{PWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;EOWlEPTB;MUCuN|kxPyEQvF2= MYnTRW5ITVJ?
IST-MES1 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX3d45KSzVyPUGwMlQ2PjRizszN NW\0O2k3W0GQR1XS
GR-ST MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjwfohKSzVyPUGwMlUxOjRizszN NEnRdXhUSU6JRWK=
SUP-T1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFyLkezNVch|ryP NF7mT3NUSU6JRWK=
NB5 NYPzNVVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn2TWM2OD1zMD65NFIzKM7:TR?= NYTmOHE6W0GQR1XS
MZ1-PC NVLsfY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrSeVZmUUN3ME2xNE46PTdzIN88US=> MYrTRW5ITVJ?
SK-CO-1 NX7GW5VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHEN|ZqUUN3ME2xNE46QTNzIN88US=> Mn\PV2FPT0WU
Capan-2 NFq3V|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHuXHFKSzVyPUGxMlMyQThizszN M2XSRXNCVkeHUh?=
697 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PvZ2lEPTB;MUGuOlc2PyEQvF2= NF:2eJBUSU6JRWK=
REH NI\PXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vGUmlEPTB;MUGuO|Q2OSEQvF2= NV3HVFdWW0GQR1XS
GI-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC0U|BKSzVyPUGxMlg3OTVizszN MkC3V2FPT0WU
BB65-RCC Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnNXIhKSzVyPUGyMlA6OTZizszN MUXTRW5ITVJ?
NCI-H1651 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13UfWlEPTB;MUKuNlQ4QCEQvF2= MWrTRW5ITVJ?
NCI-H1618 NUC4TmRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTJWmxtUUN3ME2xNk4{QTd4IN88US=> M3[wRXNCVkeHUh?=
NCI-H2081 NXzIcZhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULaS3pvUUN3ME2xNk43OTRzIN88US=> MYfTRW5ITVJ?
GCIY NV;Hem5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z6PGlEPTB;MUKuO|IyOyEQvF2= NHTmW|JUSU6JRWK=
NY NY\0PGQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjmdll3UUN3ME2xN{4xPjR|IN88US=> M{K3VHNCVkeHUh?=
PANC-03-27 NYDoPItNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXqTWM2OD1zMz6wPFA4KM7:TR?= MV\TRW5ITVJ?
BHY Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\3SWlEPTB;MUOuNlEzOSEQvF2= M3\1SHNCVkeHUh?=
SK-OV-3 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF|LkO3OlMh|ryP MV3TRW5ITVJ?
5637 NI[wSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7UTINOUUN3ME2xN{44PzV7IN88US=> NE\ocI1USU6JRWK=
LC-1F M1;SfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfpTWM2OD1zND6wN|U3KM7:TR?= Mn7EV2FPT0WU
SNB75 NHju[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPTTWM2OD1zND6wN|g{KM7:TR?= NYPkUVhVW0GQR1XS
CHP-212 M3PMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\E[|c5UUN3ME2xOE4xPDZ2IN88US=> NXrRSlA6W0GQR1XS
HT-1376 M1\2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzEcJVKSzVyPUG0MlEyOjZizszN NGq1SXdUSU6JRWK=
MONO-MAC-6 M3;zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTsTWM2OD1zND6xOVAzKM7:TR?= M{XhbnNCVkeHUh?=
CA46 M4G2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LO[2lEPTB;MUSuNVgzPyEQvF2= NVnrWYNSW0GQR1XS
SCC-15 M4nXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L0cGlEPTB;MUSuOVU5OyEQvF2= MnTZV2FPT0WU
ATN-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW3bIFKSzVyPUG0MlY3OjdizszN NVyzSIJXW0GQR1XS
NCI-H2405 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXQNpRKSzVyPUG0MlgyPTdizszN NX\MNnJwW0GQR1XS
NCI-H716 NEf0NZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHlNpdKSzVyPUG0Mlg1QTNizszN Ml\jV2FPT0WU
SW620 NVz5eGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILZbWtKSzVyPUG0MlkxOTRizszN MXXTRW5ITVJ?
NCI-H226 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLvTWM2OD1zND65NFg2KM7:TR?= M4i2VnNCVkeHUh?=
SW962 M3\4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF2Lkm0N|Ih|ryP NVjjT416W0GQR1XS
KYSE-150 NVPoflZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDDTWM2OD1zND65OVUh|ryP MU\TRW5ITVJ?
OCUB-M NVWyZVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fXNWlEPTB;MUSuPVg5OyEQvF2= NX3TSW5yW0GQR1XS
ES7 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr0TWM2OD1zNT6wPVg1KM7:TR?= MWjTRW5ITVJ?
SW1463 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f3e2lEPTB;MUWuOFIzOyEQvF2= MXLTRW5ITVJ?
CAKI-1 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF3LkWzOFYh|ryP NFHVcpBUSU6JRWK=
MKN28 NWLUVGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXrTWM2OD1zNT61OFc6KM7:TR?= MnKwV2FPT0WU
SW13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDwPHNsUUN3ME2xOU43OThizszN M2m2RnNCVkeHUh?=
A3-KAW MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLPO4RxUUN3ME2xOU46Pjl5IN88US=> NGXyNmJUSU6JRWK=
LU-65 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;LRYZKSzVyPUG1Mlk4PjhizszN NX75ZZJXW0GQR1XS
Calu-1 M1fDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjxdmFKSzVyPUG2MlA{PjhizszN MXLTRW5ITVJ?
ST486 NIrhVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Gzc2lEPTB;MU[uNFQ{OSEQvF2= NYTjNWNqW0GQR1XS
BB30-HNC Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTvTWM2OD1zNj6xNlQ3KM7:TR?= MX7TRW5ITVJ?
EGI-1 NHHwc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf5bVVKSzVyPUG2MlQ1PiEQvF2= NGHqdppUSU6JRWK=
SH-4 NYfpWJJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi4XGdKSzVyPUG2MlQ4OzFizszN M{DFd3NCVkeHUh?=
MN-60 M3fSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G1eWlEPTB;MUeuNlI6PyEQvF2= NHuwdo1USU6JRWK=
MPP-89 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfpXHJ1UUN3ME2xO{4zPDV7IN88US=> NIHLOmxUSU6JRWK=
A2780 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF5LkSxN|kh|ryP MmT0V2FPT0WU
Daoy Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF5LkS2PVUh|ryP M1roeXNCVkeHUh?=
NCI-H2126 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrKUlBUUUN3ME2xO{41PzdzIN88US=> M4m0O3NCVkeHUh?=
NCI-H1563 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m3[WlEPTB;MUeuOFkyPyEQvF2= M3jpb3NCVkeHUh?=
8-MG-BA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnB[25UUUN3ME2xO{43PjR6IN88US=> NFXnfIFUSU6JRWK=
786-0 M2rFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofmTWM2OD1zNz64N|U{KM7:TR?= MWHTRW5ITVJ?
AM-38 NGra[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3uTWM2OD1zNz65N|A3KM7:TR?= M3;rWnNCVkeHUh?=
COLO-824 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjkTWM2OD1zOD60OFM3KM7:TR?= MW\TRW5ITVJ?
SK-MEL-30 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjWZXNKSzVyPUG4MlUxQDJizszN M2X5dXNCVkeHUh?=
CESS NF\tfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:2bpZKSzVyPUG4Mlc3ODlizszN MUjTRW5ITVJ?
BL-70 M1fkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTPVJJLUUN3ME2xPE45OTV4IN88US=> Mk\HV2FPT0WU
NCI-H2170 M4LyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPKTWM2OD1zOD65NVc6KM7:TR?= MY\TRW5ITVJ?
HT-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jBUGlEPTB;MUiuPVg{KM7:TR?= M1jBUXNCVkeHUh?=
BOKU NHHLRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF7LkCzPFEh|ryP NGPiZoNUSU6JRWK=
HPAF-II Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nsbWlEPTB;MUmuN|AyPSEQvF2= NF\TdJhUSU6JRWK=
KGN M3TZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLITWM2OD1zOT60O|Y2KM7:TR?= M4nvSXNCVkeHUh?=
MC-CAR M4PZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfPWmFKSzVyPUG5MlY{OTNizszN MmDPV2FPT0WU
BHT-101 NX3sd|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[xb|ZVUUN3ME2xPU44PzdizszN MlTrV2FPT0WU
SW1783 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF7Lke4NFYh|ryP M2HSe3NCVkeHUh?=
KP-N-YN NGLreZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[2fGlEPTB;MkCuNFI3OiEQvF2= MYPTRW5ITVJ?
LU-165 NVXRT3ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPFWWF1UUN3ME2yNE42PTdzIN88US=> M1XifnNCVkeHUh?=
GOTO M4DrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJyLk[0OVEh|ryP MXrTRW5ITVJ?
EFM-19 NHfBXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULEZVRXUUN3ME2yNU4xPzF4IN88US=> NUflb3FwW0GQR1XS
CTV-1 M3\ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LIcWlEPTB;MkGuNVA2PCEQvF2= M37IeXNCVkeHUh?=
HEL NETEWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\sOnhKSzVyPUKxMlQzOTZizszN NWfQZYRRW0GQR1XS
SNU-C2B M{LOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojvTWM2OD1{MT60NlYh|ryP NXm0[YJLW0GQR1XS
ECC4 M3q4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz5Z4pQUUN3ME2yNU44ODdizszN NGj1[pJUSU6JRWK=
NEC8 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDKRnBKSzVyPUKxMlg{PjhizszN NH;BcVJUSU6JRWK=
KMOE-2 M1SxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P5XmlEPTB;MkGuPFkzOSEQvF2= NWnoV5FDW0GQR1XS
NCI-H524 M125Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV21UI9GUUN3ME2yNk4xQDB6IN88US=> NI\qSVZUSU6JRWK=
WSU-NHL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInmR41KSzVyPUKyMlE2PzdizszN NY\pb|B{W0GQR1XS
SF126 NYnWeJVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PpSmlEPTB;MkKuNlQ3QSEQvF2= NFrQ[2dUSU6JRWK=
HOP-92 NX\CcYZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ{LkOxOlch|ryP NFHyUphUSU6JRWK=
CTB-1 NInPZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ{LkS2O|ch|ryP MXjTRW5ITVJ?
KYSE-270 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJ{LkmzOVch|ryP MkDvV2FPT0WU
SK-MEL-24 NGSxeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jtSmlEPTB;MkOuNVg4KM7:TR?= MUnTRW5ITVJ?
Calu-3 NEHVSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P4SmlEPTB;MkOuNlEzQCEQvF2= NHXr[mRUSU6JRWK=
GAMG NX3tcoRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLDTWM2OD1{Mz6yN|Y4KM7:TR?= NF;wSHlUSU6JRWK=
SW1573 NGfkUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnPTWM2OD1{Mz63OFE2KM7:TR?= Mn;SV2FPT0WU
MHH-NB-11 NWDyO4lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWroNJFYUUN3ME2yOE4xOTl2IN88US=> M2XqeXNCVkeHUh?=
TK10 NXLYPYVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP5TWM2OD1{ND61NFE{KM7:TR?= M4LQcXNCVkeHUh?=
LB373-MEL-D MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ2Lk[wOlQh|ryP Mn:5V2FPT0WU
KALS-1 M2rXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SydGlEPTB;MkSuO|MzPyEQvF2= M3TkcHNCVkeHUh?=
HUTU-80 NHvxZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP3TWM2OD1{NT64NFMzKM7:TR?= NXjmR5FGW0GQR1XS
HuP-T3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ4LkG2O|Qh|ryP MX\TRW5ITVJ?
OE19 NXTZXHBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nVV2lEPTB;Mk[uNlE2OyEQvF2= Mnz5V2FPT0WU
J82 M3nvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjjSotKSzVyPUK2MlI1PzFizszN Mm\4V2FPT0WU
DU-4475 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHQVlNKSzVyPUK2MlM5OTlizszN NVfk[5ZkW0GQR1XS
DMS-53 NY\LZpdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\6W2lEPTB;Mk[uOVE{QCEQvF2= NIjrWWNUSU6JRWK=
COLO-741 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnEWGtKSzVyPUK2Mlg{PDRizszN NVK4W5hbW0GQR1XS
SW48 NVfRR41[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknsTWM2OD1{Nj64PFIh|ryP M{LjWnNCVkeHUh?=
IGR-1 M4rNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGxTWM2OD1{Nj65N|M1KM7:TR?= NG\ST4JUSU6JRWK=
639-V MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6wfG5qUUN3ME2yO{4xOjR3IN88US=> MX;TRW5ITVJ?
LK-2 M2fuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETtWJRKSzVyPUK3MlQyPDFizszN NUTuPVVQW0GQR1XS
NCI-H2347 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ5Lkm2PVkh|ryP MknUV2FPT0WU
NCI-H2228 M3LmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7UPJRjUUN3ME2yPE4xQTB3IN88US=> MkDaV2FPT0WU
LS-123 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJ6LkGyOlIh|ryP NWLYVJNCW0GQR1XS
U031 NHLTV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL3TWM2OD1{OD6yOVIh|ryP NGDiRmVUSU6JRWK=
NCI-H1792 NGLkW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jjcmlEPTB;MkiuOFczOSEQvF2= NHf6bIFUSU6JRWK=
NCI-H2087 NY\TcWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ6Lke1OVIh|ryP NGO5dFNUSU6JRWK=
NCI-H2342 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1SVhKSzVyPUK5MlUzODhizszN NGjBTo9USU6JRWK=
SW626 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ7Lke1OkDPxE1? NEXnSY9USU6JRWK=
LB2518-MEL MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnETWM2OD1{OT64NVUh|ryP Moq2V2FPT0WU
RXF393 NU\aV|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPHNHBIUUN3ME2zNE4xQTV{IN88US=> NWD5fGhPW0GQR1XS
LC4-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fObGlEPTB;M{CuN|A6OiEQvF2= NXXCXplqW0GQR1XS
NCI-H1694 NIn1[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XzV2lEPTB;M{CuOlYzPCEQvF2= M4\ybnNCVkeHUh?=
K5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf3XI56UUN3ME2zNE46PzB{IN88US=> MmPBV2FPT0WU
HDLM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G3RWlEPTB;M{CuPVczPSEQvF2= NULneW54W0GQR1XS
BCPAP NEHTPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;U[IxKSzVyPUOxMlg{PzlizszN NWm2WGZWW0GQR1XS
BC-3 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj6TWM2OD1|Mj6xOFA{KM7:TR?= MmrwV2FPT0WU
LB996-RCC MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D5c2lEPTB;M{KuNlM2QCEQvF2= MmLEV2FPT0WU
NCI-H2009 NXzZNINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3RXNWUUN3ME2zNk41QThzIN88US=> MWDTRW5ITVJ?
HTC-C3 NWW5WJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfDTWM2OD1|Mz63OVE6KM7:TR?= M2XVXXNCVkeHUh?=
LAMA-84 NUXtR|VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN2LkS0NFch|ryP NV\mOHhDW0GQR1XS
CCRF-CEM M3vYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfxboRKSzVyPUO0MlU4OTVizszN NXzIS2oyW0GQR1XS
AN3-CA NY[1enFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLpTWM2OD1|NT6wOVY5KM7:TR?= NVnmSlBQW0GQR1XS
NCI-H1734 NILncWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN3LkK1OlEh|ryP M2POdnNCVkeHUh?=
Ca-Ski NIPBSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLkc2Q2UUN3ME2zOU41OTBzIN88US=> M13HPHNCVkeHUh?=
U-266 NEXqVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjkXoZYUUN3ME2zOU43OTF2IN88US=> MXPTRW5ITVJ?
SBC-5 NV:1ZXFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BNFJKSzVyPUO1Mlc4QDFizszN Mne3V2FPT0WU
GT3TKB NIHBVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHI[VJKSzVyPUO3MlEyPSEQvF2= MlHrV2FPT0WU
MDA-MB-175-VII MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DoXGlEPTB;M{euNlI1QCEQvF2= MoHYV2FPT0WU
PFSK-1 NEjsfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTN5LkK0N|Uh|ryP MVLTRW5ITVJ?
IMR-5 MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP1c2F1UUN3ME2zO{4zPDh5IN88US=> Ml[0V2FPT0WU
Daudi M4jYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjjN2VKSzVyPUO3MlM2QTdizszN M1TnUHNCVkeHUh?=
A498 M1z4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\lTWM2OD1|Nz63NlE5KM7:TR?= MlrCV2FPT0WU
SCC-4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W3TGlEPTB;M{euO|g1OyEQvF2= NH\EeYVUSU6JRWK=
COLO-680N NIDnXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN6LkK4PFUh|ryP MXfTRW5ITVJ?
SK-MES-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTN6LkOyNVUh|ryP NGGwVZNUSU6JRWK=
SR NVqz[49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;lTWM2OD1|OD61OFk2KM7:TR?= MorSV2FPT0WU
LNCaP-Clone-FGC M2HB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\USmlEPTB;M{iuOVY{PyEQvF2= NYTTRm1UW0GQR1XS
SK-HEP-1 M1HKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nRbmlEPTB;M{iuO|gzOiEQvF2= MUfTRW5ITVJ?
BPH-1 NWDV[|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nsdGlEPTB;M{iuPFMzQSEQvF2= NVe3Snd5W0GQR1XS
NCI-H1755 NIDFXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN7LkW4NVch|ryP M1j5b3NCVkeHUh?=
LXF-289 NGHVUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN7LkiwPFQh|ryP M2jRdHNCVkeHUh?=
SW1088 M3;IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rlfmlEPTB;NECuNlExPyEQvF2= NInOU5NUSU6JRWK=
MOLT-4 NEnLNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILDe21KSzVyPUSwMlI6ODFizszN MVHTRW5ITVJ?
AsPC-1 M4j0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG0TWM2OD12MD60OVg{KM7:TR?= NF\mNHlUSU6JRWK=
HOP-62 NFrQSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;PTWM2OD12MD62OVY5KM7:TR?= NWL3WnJLW0GQR1XS
A172 NGrRPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO1TWM2OD12MD64OVEyKM7:TR?= MU\TRW5ITVJ?
SN12C NX\0[WNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\uTWM2OD12MD65N|g2KM7:TR?= M1HFU3NCVkeHUh?=
MDA-MB-231 M3KwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M372XWlEPTB;NECuPVg6QCEQvF2= NXT1WlhvW0GQR1XS
RPMI-2650 M3TtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfGVmhXUUN3ME20NU4yPTl|IN88US=> NETGfnBUSU6JRWK=
KYSE-140 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRzLkixNlMh|ryP M4HNdXNCVkeHUh?=
KINGS-1 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTR{LkS2PVch|ryP NU\oTpBXW0GQR1XS
HSC-3 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnuTWM2OD12Mj62OlYyKM7:TR?= MlH6V2FPT0WU
PC-14 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTR|LkG4PFIh|ryP MWnTRW5ITVJ?
COR-L105 NXfZe5FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHvfGVKUUN3ME20N{43PTB{IN88US=> NF3GVJlUSU6JRWK=
BE-13 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zHRmlEPTB;NESuNlM4OSEQvF2= NILhemtUSU6JRWK=
NCI-H661 NHjwT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSyTWM2OD12ND6yPVU5KM7:TR?= MYjTRW5ITVJ?
IST-MEL1 NGn1TlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fvSmlEPTB;NESuN|U6QSEQvF2= NGf6[o5USU6JRWK=
HCC1806 M{D4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjwTWM2OD12ND61PFc{KM7:TR?= NHOyb2hUSU6JRWK=
COLO-800 NXnoN3RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf4T4NKSzVyPUS0Mlg1PTNizszN MYfTRW5ITVJ?
IST-SL2 NVf6WWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nzOGlEPTB;NEWuNVI1PyEQvF2= NELuOZBUSU6JRWK=
8305C NXX5OpVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jmbGlEPTB;NEWuN|A6KM7:TR?= MmLFV2FPT0WU
UACC-62 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTR4LkK4O|Uh|ryP NFzSWnVUSU6JRWK=
COR-L23 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR5LkG5PUDPxE1? NF:zRoxUSU6JRWK=
EFE-184 NIW3eYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfmTWM2OD12Nz6zPFgh|ryP MYTTRW5ITVJ?
DMS-114 M{K3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV31NJZCUUN3ME20O{41OTR7IN88US=> MkHPV2FPT0WU
KYSE-520 M1vUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR6LkWzNVUh|ryP MkP3V2FPT0WU
SNG-M NGDtSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX3OZBVUUN3ME20PU41OzRizszN M2TrOXNCVkeHUh?=
A2058 M1HE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe2TWM2OD12OT60PFg2KM7:TR?= MnLRV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型,抑制肿瘤生长,按 75 mg / kg剂量处理,导致100% TGI和 55% 衰退,按25 mg/kg剂量处理,导致 60% TGI,没有衰退。OSI-906处理犬,大鼠和小鼠,诱导不同的消除半衰期,消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠,每天一次,Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天,提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型,在4 和24小时间最大程度抑制IGF-IR磷酸化(80%),血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠,处理2,4,24小时,抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型,抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中,使用聚 (Glu:Tyr)作为底物,结合到96孔实验板表面,使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物,通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中,人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白,且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验,除非另有说明,取三次测量的最小值。
细胞实验:[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖,细胞接种在含FCS 10%的合适培养基上,在不同浓度OSI-906存在时,温育3天。通过细胞内ATP含量的荧光量化,使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分,通过在不同浓度 OSI-906存在时的细胞密度除以对照组(只用DMSO处理)细胞密度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理,每天一次,持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O

CAS号 867160-71-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID